FIG. 1.

ADHD symptom scores (A) and noncompliance (B) over time by original treatment assignment, and by PT versus no PT (C, D), last observation carried forward to week 34. Although some of the week 34 end-of-treatment improvement is lost by week 78 FU, the endpoint remains significantly better than baseline for all originally assigned treatment groups. Those originally assigned placebo had an open atomoxetine trial after week 10 if needed. Difference in change from baseline to week 78 between placebo and 3 pooled active treatments: p = 0.044 for SNAP ADHD rating and p = 0.023 for HSQ noncompliance score. Change difference between PT and no PT is not significant. Vertical line at week 34 indicates end-of-study treatment. ADHD, attention-deficit/hyperactivity disorder.